Anders Hove and Bong Koh’s VHCP Management disclosed a large increase in its Ocera Therapeutics (OCRX) stake. According to the latest 13F filings, Venrock had 700K shares of OCRX at the end of December. A new filing reveals an increase of almost 1.2 million shares in Venrock’s OCRX stake.
At Q4’s end, a total of 10 of the hedge funds tracked by Insider Monkey were long this stock, a change of 11% from the previous quarter. According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Great Point Partners, managed by Jeffrey Jay and David Kroin, holds the biggest position in Ocera Therapeutics Inc (NASDAQ:OCRX). Great Point Partners has a $6.1 million position in the stock, comprising 2.6% of its 13F portfolio. On Great Point Partners’s heels is QVT Financial, led by Daniel Gold, holding a $2.9 million position; 0.2% of its 13F portfolio is allocated to the stock. Other hedge funds and institutional investors that are bullish include Israel Englander’s Millennium Management and Hal Mintz’s Sabby Capital.
As industrywide interest jumped, specific money managers were breaking ground themselves. Citadel Investment Group, managed by Ken Griffin, initiated the most outsized position in Ocera Therapeutics Inc (NASDAQ:OCRX). Citadel Investment Group had $0.1 million invested in the company at the end of the quarter.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Venrock Healthcare Capital Partners||0||1,885,668||0||1,885,668||1,885,668||9.1%|
|VHCP Co-Investment Holdings||0||1,885,668||0||1,885,668||1,885,668||9.1%|
|Venrock Healthcare Capital Partners II||0||1,885,668||0||1,885,668||1,885,668||9.1%|
|VHCP Co-Investment Holdings II||0||1,885,668||0||1,885,668||1,885,668||9.1%|
|VHCP Management II||0||1,885,668||0||1,885,668||1,885,668||9.1%|
Page 1 of 18 SEC Filing
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.